TransMolecular was a biotech company located in Birmingham, Alabama. It was geared to finding anti-cancer targeted drugs.[1]
| Industry | Biotech |
|---|---|
| Headquarters | |
| Parent | Morphotek, Inc. (from 2011) |
| Website | transmolecular |
TransMolecular, Inc. engaged in discovering, developing, and commercializing therapies for glioma, metastatic brain tumors, and cancers. It developed TM601, a synthetically-produced polypeptide that was derived from scorpion venom, which is used to specifically target tumors in the treatment of cancer.[2] The company was founded in 1996. In 2003, Fortune Magazine listed the company as one of the 14 "most exciting, innovative companies in the nation".[3][4]
In March 2011, TransMolecular's assets were purchased by Morphotek, a subsidiary of the Japanese pharmaceutical company Eisai.[5]
References
edit- ^ McIntosh, Charlotte (23 Oct 2000). "Hope for brain cancer cure". Birmingham Post-Herald. p. B1.
- ^ Kowalczyk, Liz (30 Jan 1999). "Scorpion sting may be cure for brain cancer". The Anniston Star. Anniston, Alabama. p. 4B.
- ^ Centers, Jessica (15 Mar 2004). "Technology incubator". The Anniston Star. Anniston, Alabama. p. 1B.
- ^ Keeney, Jennifer; Kwon, Beth; Overfelt, Maggie (1 Feb 2003). "14 Hot Startups". CNN Money. Retrieved 21 December 2023.
- ^ "Morphotek Acquires TransMolecular's Tumor-Targeting Drug Delivery Assets". Genetic Engineering & Biotechnology News. 5 April 2011. Retrieved 21 December 2023.
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |